Dear colleagues,
The following news items have been published in the previous month:
-
03 May 2024:
Consultation: benzylpenicillin breakpoints for S.pneumoniae and Viridans group streptococci
EUCAST consultation (3 May - 14 June) on breakpoints for Streptococcus pneumoniae and viridans group streptococci.
-
03 May 2024:
Aztreonam-avibactam and cefepime-enmetazobactam now available.
Aztreonam-avibactam has now obtained regulatory approval and breakpoints from EMA and EUCAST for Enterobacterales. These are S≤4, R>4 mg/L.
Disk diffusion criteria and QC targets and ranges will be published shortly. There are no breakpoints for other species.
Cefepime-enmtazobactam has now obtained regulatory approval breakpoints from EMA and EUCAST for Enterobacterales. These are S≤4, R>4 mg/L.
Disk diffusion criteria and QC targets and ranges will be published shortly. There are no breakpoints for other species.
The new agents will be part of the next EUCAST breakpoint table 15.0
(1st of January 2025). In the meantime we will soon publish an addendum
for the two agents with information on disk contents (potencies), zone
diameter correlates and QC criteria.
-
24 Apr 2024:
Salmonella enterica - multinational zone diameter distributions uploaded
Salmonella enterica zone diameter distributions and ECOFFs
for thousands of isolates from many countries were uploaded. The
contributions were organised through an ECDC project using phenotypic
antimicrobial susceptibility data reported to ECDC from fourteen
countries (Austria, Belgium, Croatia, Czechia, Finland, France, Greece,
Italy, Luxembourg, Norway, Poland, Portugal, Slovenia and Spain) in the
Food- and Waterborne Diseases and Zoonoses Network. These data and have
now been used to better define wild type zone diameter
distributions for Salmonella isolates. ECOFFs were determined using a
novel statistical programme. Below is a link for anyone interested in a
systematic comparison of "before and after".
-
24 Apr 2024:
Information for industry - reference and standardised AST.
EUCAST guidance on how to determine MIC values and develop distributions (and zone diameter distributions) for new agents in preparation for EUCAST and EMA evaluation.
The development of new agents requires agreement and acceptance of
the data generated in support of decisions on clinical breakpoints, wild
type MIC distributions, ECOFFs and routine susceptibility testing
correlates. EUCAST and CLSI both favour the use of the non-modified ISO
recommended reference broth microdilution for this purpose, and only
occasionally is there good reason to deviate from this. When this is
considered necessary it is strongly adviced that it is with the
agreement and full understanding of standards committees and agencies,
such as CLSI, EUCAST, FDA and EMA.
-
21 Apr 2024:
Warning against the use of AST devices for amphotericin B testing of Candida auris.
The Warning pertains to the following AST methods for amphotericin B and C. auris.
- Etest, (Etest, bioMerieux), gradient strip
- Mic Test Strip (MTS, Liofilchem), gradient strip
- Vitek 2 system (bioMerieux)
- Sensititre Yeast One (Thermofisher)
-
01 Apr 2024:
Dalbavancin MIC distributions and ECOFFs
Dalbavancin MIC distributions and ECOFFs,
particularly for Enterococcus faecalis and E. faecium, made available.
This is in response to frequent requests for more information on
dalbavancin MIC distributions.
Please visit the EUCAST News page to read more.
All changes to the EUCAST website and to AST recommendations and guidance are listed in a table on the EUCAST website!
With kind regards,
EUCAST
|
